Curis And Cyclacel Pharmaceuticals On The List Of Winners And Losers Of Tuesday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Curis, Yunhong CTI Ltd., and TherapeuticsMD.

Rank Financial Asset Price Change Updated (EST)
1 Curis (CRIS) 7.35 24.37% 2023-11-19 21:07:06
2 Yunhong CTI Ltd. (CTIB) 2.40 21.83% 2023-11-19 22:43:06
3 TherapeuticsMD (TXMD) 2.69 18.5% 2023-11-20 12:17:33
4 Charles & Colvard Ltd. (CTHR) 0.41 12.85% 2023-11-19 22:42:06
5 CommScope Holding Company (COMM) 1.90 12.43% 2023-11-19 19:11:06
6 The Dixie Group (DXYN) 0.69 11.27% 2023-11-20 06:23:06
7 Canopy Growth (CGC) 0.61 10.86% 2023-11-20 12:22:59
8 Eltek Ltd. (ELTK) 12.76 10.67% 2023-11-20 07:47:05
9 Cyclacel Pharmaceuticals (CYCCP) 8.80 10% 2023-11-20 01:07:05
10 Fate Therapeutics (FATE) 2.62 8.02% 2023-11-20 13:12:05

The three biggest losers today are Cyclacel Pharmaceuticals, Educational Development Corporation, and CVD Equipment Corporation.

Rank Financial Asset Price Change Updated (EST)
1 Cyclacel Pharmaceuticals (CYCC) 0.30 -13.5% 2023-11-20 01:06:05
2 Educational Development Corporation (EDUC) 0.81 -12.05% 2023-11-20 07:12:05
3 CVD Equipment Corporation (CVV) 4.99 -10.09% 2023-11-19 23:15:05
4 Xenetic Biosciences (XBIO) 3.04 -7.75% 2023-11-20 12:17:45
5 NeuroMetrix (NURO) 0.47 -7.49% 2023-11-20 12:50:48
6 ImmunoGen (IMGN) 14.98 -6.98% 2023-11-20 12:13:09
7 Nikola (NKLA) 0.99 -4.67% 2023-11-20 12:16:48
8 Farmer Brothers Company (FARM) 2.50 -4.58% 2023-11-20 13:10:05
9 Aware, Inc. (AWRE) 1.63 -4.41% 2023-11-20 12:11:01
10 Lyft (LYFT) 10.16 -3.99% 2023-11-20 12:16:36

Winners today

1. Curis (CRIS) – 24.37%

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

NASDAQ ended the session with Curis jumping 24.37% to $7.35 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Curis has a trailing twelve months EPS of $-9.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -110.22%.

Volume

Today’s last reported volume for Curis is 1786780 which is 864.48% above its average volume of 185257.

Sales Growth

Curis’s sales growth is 5% for the present quarter and 13.2% for the next.

More news about Curis.

2. Yunhong CTI Ltd. (CTIB) – 21.83%

Yunhong CTI Ltd. develops, produces, distributes, and sells consumer products in the United States and internationally. It offers novelty products, including foil balloons; latex balloons under the Partyloons name; and toy balloon products, which include punch balls, water bombs, and Animal Twisties, as well as other inflatable toy items. The company also offers packaging films and custom film products for food, and other commercial and packaging applications; produces and distributes home organization and container products; assembles and sells Candy Blossom product line; and distribute party goods. It primarily serves various retail outlets, including general merchandise stores, discount and drugstore chains, grocery chains, card and gift shops, and party goods stores, as well as florists and balloon decorators. The company sells its products directly, as well as through a network of distributors and wholesalers, retail chains, and independent sales representatives. The company was formerly known as CTI Industries Corporation and changed its name to Yunhong CTI Ltd. in January 2020. Yunhong CTI Ltd. was founded in 1975 and is headquartered in Lake Barrington, Illinois.

NASDAQ ended the session with Yunhong CTI Ltd. rising 21.83% to $2.40 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Yunhong CTI Ltd. has a trailing twelve months EPS of $-0.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.02%.

Moving Average

Yunhong CTI Ltd.’s value is way above its 50-day moving average of $2.02 and way above its 200-day moving average of $1.78.

Yearly Top and Bottom Value

Yunhong CTI Ltd.’s stock is valued at $2.40 at 01:32 EST, way under its 52-week high of $2.80 and way above its 52-week low of $0.33.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.1%, now sitting on 16.94M for the twelve trailing months.

Volume

Today’s last reported volume for Yunhong CTI Ltd. is 239336 which is 335.02% above its average volume of 55017.

More news about Yunhong CTI Ltd..

3. TherapeuticsMD (TXMD) – 18.5%

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD jumping 18.5% to $2.69 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $3.41.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.79. Meaning, the purchaser of the share is investing $0.79 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1134.2%.

Volume

Today’s last reported volume for TherapeuticsMD is 33029 which is 73.34% above its average volume of 19054.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TherapeuticsMD’s EBITDA is -15.58.

Revenue Growth

Year-on-year quarterly revenue growth grew by 25.6%, now sitting on 69.77M for the twelve trailing months.

More news about TherapeuticsMD.

4. Charles & Colvard Ltd. (CTHR) – 12.85%

Charles & Colvard, Ltd. operates as a fine jewelry company in the United States and internationally. The company manufactures, markets, and distributes moissanite jewels and finished moissanite jewelry under the Charles & Colvard Created Moissanite brand; and premium moissanite gemstones under the Forever One brand name. It also markets and distributes lab grown diamonds, and finished jewelry with lab grown diamonds under the Caydia brand. The company sells its products at wholesale prices to distributors, manufacturers, retailers, and designers; and to end-consumers at retail prices through charlesandcolvard.com, third-party online marketplaces, drop-ship, and other e-commerce outlets. Charles & Colvard, Ltd. was founded in 1995 and is headquartered in Morrisville, North Carolina.

NASDAQ ended the session with Charles & Colvard Ltd. rising 12.85% to $0.41 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Charles & Colvard Ltd. has a trailing twelve months EPS of $-0.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.42%.

Moving Average

Charles & Colvard Ltd.’s worth is way under its 50-day moving average of $0.51 and way below its 200-day moving average of $0.82.

Volume

Today’s last reported volume for Charles & Colvard Ltd. is 598161 which is 153.87% above its average volume of 235615.

Yearly Top and Bottom Value

Charles & Colvard Ltd.’s stock is valued at $0.41 at 01:32 EST, way below its 52-week high of $1.26 and way above its 52-week low of $0.28.

More news about Charles & Colvard Ltd..

5. CommScope Holding Company (COMM) – 12.43%

CommScope Holding Company, Inc. provides infrastructure solutions for communications and entertainment networks. It operates through four segments: Broadband Networks (Broadband), Home Networks (Home), Outdoor Wireless Networks (OWN), and Venue and Campus Networks (VCN).The Broadband segment provides a converged cable access platform, passive optical networking products, video systems, access technologies, fiber and coaxial cables, fiber and copper connectivity products, and hardened closures to the telco and cable provider broadband market. The Home segment offers subscriber-based solutions that support broadband and video applications; devices that provide residential connectivity to a service provider's network, such as digital subscriber line, cable modems, and telephony and data gateways that incorporate routing and Wi-Fi functionality; and set-top boxes that support cable, satellite, and Internet protocol television content delivery, which include digital video recorders, high definition set-top boxes, and hybrid set-top devices. The OWN segment provides base station antennas, RF filters, tower connectivity, microwave antennas, metro cell products, cabinets, steel, accessories, spectrum access system, and Comsearch products to the macro and metro cell markets. The VCN segment products include Wi-Fi and switching, distributed antenna systems, licensed and unlicensed small cells, enterprise fiber, and copper infrastructures for campuses, venues, data centers, and buildings. It serves in the United States, Europe, the Middle East, Africa, the Asia Pacific, Caribbean and Latin America, and Canada through specialized resellers and distributors, satellite video distributors, and system integrators, as well as directly to customers. The company was formerly known as Cedar I Holding Company, Inc. and changed its name to CommScope Holding Company, Inc. in January 2011. CommScope Holding Company, Inc. was founded in 1976 and is headquartered in Hickory, North Carolina.

NASDAQ ended the session with CommScope Holding Company rising 12.43% to $1.90 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, CommScope Holding Company has a trailing twelve months EPS of $-10.04.

Earnings Before Interest, Taxes, Depreciation, and Amortization

CommScope Holding Company’s EBITDA is 1.35.

Sales Growth

CommScope Holding Company’s sales growth for the current quarter is negative 35%.

More news about CommScope Holding Company.

6. The Dixie Group (DXYN) – 11.27%

The Dixie Group, Inc. manufactures, markets, and sells floorcovering products to residential customers in North America and internationally. It offers residential carpets, custom rugs, and engineered wood products under the Fabrica brand for interior decorators and designers, selected retailers and furniture stores, luxury home builders, and manufacturers of luxury motor coaches and yachts; and specialty carpets and rugs for the high-end residential marketplace, as well as luxury vinyl flooring products and broadloom carpet products under the Masland Residential brand name through the interior design community and specialty floorcovering retailers. The company also provides residential tufted broadloom carpets and rugs to selected retailers and home centers under the Dixie Home and private label brands, as well as luxury vinyl flooring products to the marketplace it serves. The company was founded in 1920 and is based in Dalton, Georgia.

NASDAQ ended the session with The Dixie Group rising 11.27% to $0.69 on Tuesday, after three successive sessions in a row of gains. NASDAQ rose 1.13% to $14,284.53, after four sequential sessions in a row of gains, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, The Dixie Group has a trailing twelve months EPS of $-1.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.55%.

Moving Average

The Dixie Group’s worth is above its 50-day moving average of $0.64 and way below its 200-day moving average of $0.88.

Earnings Before Interest, Taxes, Depreciation, and Amortization

The Dixie Group’s EBITDA is 0.45.

Yearly Top and Bottom Value

The Dixie Group’s stock is valued at $0.69 at 01:32 EST, way below its 52-week high of $1.36 and way higher than its 52-week low of $0.46.

Volume

Today’s last reported volume for The Dixie Group is 25220 which is 29.1% below its average volume of 35575.

More news about The Dixie Group.

7. Canopy Growth (CGC) – 10.86%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 10.86% to $0.61 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

More news about Canopy Growth.

8. Eltek Ltd. (ELTK) – 10.67%

Eltek Ltd. manufactures, markets, and sells printed circuit boards (PCBs) in Israel, Europe, North America, India, the Netherlands, and internationally. The company offers a range of custom designed PCBs, including rigid, double-sided, and multi-layer PCBs, and flexible circuitry boards. It also offers high density interconnect, flex-rigid, and multi-layered boards. It primarily serves manufacturers of defense and aerospace, medical, industrial, telecom, and networking equipment, as well as contract electronic manufacturers and others. The company markets and sells its products primarily through direct sales personnel, sales representatives, and PCB trading and manufacturing companies. Eltek Ltd. was incorporated in 1970 and is headquartered in Petach Tikva, Israel. Eltek Ltd. is a subsidiary of Nistec Golan Ltd.

NASDAQ ended the session with Eltek Ltd. jumping 10.67% to $12.76 on Tuesday, following the last session’s upward trend. NASDAQ rose 1.13% to $14,284.53, after four consecutive sessions in a row of gains, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Eltek Ltd. has a trailing twelve months EPS of $0.8.

PE Ratio

Eltek Ltd. has a trailing twelve months price to earnings ratio of 15.95. Meaning, the purchaser of the share is investing $15.95 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.41%.

Volume

Today’s last reported volume for Eltek Ltd. is 118948 which is 158.43% above its average volume of 46026.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Dec 8, 2022, the estimated forward annual dividend rate is 0.17 and the estimated forward annual dividend yield is 1.33%.

More news about Eltek Ltd..

9. Cyclacel Pharmaceuticals (CYCCP) – 10%

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

NASDAQ ended the session with Cyclacel Pharmaceuticals jumping 10% to $8.80 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Cyclacel Pharmaceuticals has a trailing twelve months EPS of $-2.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -187.51%.

Moving Average

Cyclacel Pharmaceuticals’s value is way under its 50-day moving average of $12.54 and way below its 200-day moving average of $13.76.

Yearly Top and Bottom Value

Cyclacel Pharmaceuticals’s stock is valued at $8.80 at 01:32 EST, way under its 52-week high of $22.58 and way above its 52-week low of $5.25.

Volume

Today’s last reported volume for Cyclacel Pharmaceuticals is 2090 which is 25.59% below its average volume of 2809.

More news about Cyclacel Pharmaceuticals.

10. Fate Therapeutics (FATE) – 8.02%

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

NASDAQ ended the session with Fate Therapeutics jumping 8.02% to $2.62 on Tuesday, following the last session’s upward trend. NASDAQ jumped 1.13% to $14,284.53, after four sequential sessions in a row of gains, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Fate Therapeutics has a trailing twelve months EPS of $-1.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.61%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is 10.3% and a drop 178.9% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 87%, now sitting on 106.21M for the twelve trailing months.

Sales Growth

Fate Therapeutics’s sales growth is negative 96.3% for the current quarter and negative 98% for the next.

More news about Fate Therapeutics.

Losers Today

1. Cyclacel Pharmaceuticals (CYCC) – -13.5%

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

NASDAQ ended the session with Cyclacel Pharmaceuticals sliding 13.5% to $0.30 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Cyclacel Pharmaceuticals has a trailing twelve months EPS of $-1.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -187.51%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Cyclacel Pharmaceuticals’s EBITDA is -5.55.

Yearly Top and Bottom Value

Cyclacel Pharmaceuticals’s stock is valued at $0.30 at 01:32 EST, way below its 52-week high of $1.17 and higher than its 52-week low of $0.28.

Moving Average

Cyclacel Pharmaceuticals’s worth is way below its 50-day moving average of $0.45 and way below its 200-day moving average of $0.60.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 31.7% and 17%, respectively.

More news about Cyclacel Pharmaceuticals.

2. Educational Development Corporation (EDUC) – -12.05%

Educational Development Corporation, a publishing company, operates as a trade co-publisher of educational children's books in the United States. It operates through two segments, Publishing and Usborne Books & More (UBAM). The company offers various books, including touchy-feely board books, activity books and flashcards, adventure and search books, art books, sticker books, and foreign language books, as well as internet-linked books comprising science and math titles, and chapter books and novels. Educational Development Corporation markets its products to retail accounts, which include book, school supply, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers, and its internal tele-sales group; and through a network of independent sales consultants through internet sales, direct sales, home shows, and book fairs. Educational Development Corporation was incorporated in 1965 and is headquartered in Tulsa, Oklahoma.

NASDAQ ended the session with Educational Development Corporation falling 12.05% to $0.81 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Educational Development Corporation has a trailing twelve months EPS of $-0.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.77%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 45.4%, now sitting on 70.37M for the twelve trailing months.

More news about Educational Development Corporation.

3. CVD Equipment Corporation (CVV) – -10.09%

CVD Equipment Corporation designs, develops, manufactures, and sells process equipment and solutions that are used to develop and manufacture materials and coatings for research and industrial applications in the United States and internationally. It operates through three segments: CVD, SDC, and CVD Materials. The company offers chemical vapor deposition systems for use in the research, development, and manufacture of aerospace, medical components, semiconductors, LEDs, carbon nanotubes, nanowires, solar cells, and other industrial applications; and rapid thermal processing systems for use in implant activation, oxidation, silicide formation, and other processes. It also provides annealing, diffusion, and low pressure chemical vapor deposition furnaces for use in diffusion, oxidation, implant anneal, solder reflow, solar cell manufacturing, and other processes; and gas and liquid control systems, such as gas cylinder storage cabinets, custom gas and chemical delivery systems, gas and liquid valve manifold boxes, and gas isolation boxes for semiconductor fabrication processes, solar cells, LEDs, carbon nanotubes, nanowires, and industrial applications. In addition, the company offers standard and custom fabricated quartz-ware used in its equipment and other customer tools, as well as repair and replacement services for existing quartz-ware. Further, it provides MesoPlasma direct write printing, a materials deposition process that provides instrumentation, fine feature patterns, and coatings onto conformal components; and Tantaline corrosion resistant coating for valves, fittings, fasteners, vessels, bellows, and custom designed items, as well as offers carbon composites and electronic materials. The company sells its products primarily to aerospace/defense, medical, electronic component manufacturers, universities, and government and industrial laboratories. CVD Equipment Corporation was incorporated in 1982 and is headquartered in Central Islip, New York.

NASDAQ ended the session with CVD Equipment Corporation sliding 10.09% to $4.99 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, CVD Equipment Corporation has a trailing twelve months EPS of $-0.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.28%.

Volume

Today’s last reported volume for CVD Equipment Corporation is 69877 which is 351.84% above its average volume of 15465.

Yearly Top and Bottom Value

CVD Equipment Corporation’s stock is valued at $4.99 at 01:32 EST, way below its 52-week high of $15.82 and higher than its 52-week low of $4.95.

Revenue Growth

Year-on-year quarterly revenue growth declined by 23.2%, now sitting on 27.23M for the twelve trailing months.

More news about CVD Equipment Corporation.

4. Xenetic Biosciences (XBIO) – -7.75%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences falling 7.75% to $3.04 on Tuesday, following the last session’s upward trend. NASDAQ jumped 1.13% to $14,284.53, after four sequential sessions in a row of gains, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.99%.

Sales Growth

Xenetic Biosciences’s sales growth for the current quarter is 39.9%.

Volume

Today’s last reported volume for Xenetic Biosciences is 542 which is 93.13% below its average volume of 7898.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Xenetic Biosciences’s EBITDA is 5.81.

More news about Xenetic Biosciences.

5. NeuroMetrix (NURO) – -7.49%

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix dropping 7.49% to $0.47 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.61%.

More news about NeuroMetrix.

6. ImmunoGen (IMGN) – -6.98%

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with ImmunoGen dropping 6.98% to $14.98 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.88%.

Sales Growth

ImmunoGen’s sales growth is 209.7% for the ongoing quarter and 149.8% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ImmunoGen’s stock is considered to be oversold (<=20).

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 152.2% and 143.8%, respectively.

More news about ImmunoGen.

7. Nikola (NKLA) – -4.67%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola sliding 4.67% to $0.99 on Tuesday, following the last session’s upward trend. NASDAQ rose 1.13% to $14,284.53, after four consecutive sessions in a row of gains, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -132.55%.

Yearly Top and Bottom Value

Nikola’s stock is valued at $0.99 at 01:32 EST, way under its 52-week high of $3.97 and way higher than its 52-week low of $0.52.

More news about Nikola.

8. Farmer Brothers Company (FARM) – -4.58%

Farmer Bros. Co. engages in the roasting, wholesale, equipment servicing, and distribution of coffee, tea, and culinary products in the United States. The company offers roast and ground coffee; frozen liquid coffee; flavoured and unflavoured iced and hot teas; culinary products, including spices, pancake and biscuit mixes, gravy and sauce mixes, soup bases, dressings, and syrups and sauces, as well as coffee filters, cups, sugar, and creamers; and other beverages comprising cappuccino, cocoa, granitas, and other blender-based beverages and concentrated and ready-to-drink cold brew and iced coffee. It serves small independent restaurants, foodservice operators, and large institutional buyers, as well as consumers. The company distributes its products through direct-store-delivery network, and common carriers or third-party distributors, as well as Website. The company was founded in 1912 and is headquartered in Northlake, Texas.

NASDAQ ended the session with Farmer Brothers Company sliding 4.58% to $2.50 on Tuesday while NASDAQ rose 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Farmer Brothers Company has a trailing twelve months EPS of $-1.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.15%.

Yearly Top and Bottom Value

Farmer Brothers Company’s stock is valued at $2.50 at 01:32 EST, way under its 52-week high of $5.95 and way above its 52-week low of $1.75.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Farmer Brothers Company’s EBITDA is 0.29.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 71.2% and 71.9%, respectively.

Volume

Today’s last reported volume for Farmer Brothers Company is 31631 which is 68.37% below its average volume of 100023.

More news about Farmer Brothers Company.

9. Aware, Inc. (AWRE) – -4.41%

Aware, Inc., a authentication company, provides biometrics software products and solutions for government agencies and commercial entities in the United States, Brazil, the United Kingdom, and internationally. The company offers biometric software solution, which includes Knomi, a mobile biometric framework which provides multiple biometric modality options; AwareABIS, an automated biometric identification system used for large-scale biometric identification and deduplication; AFIX suite used for small-scale law enforcement focused biometric identification; and AFIX Tracker for fingerprint, palmprint, and latent print identification. It also provides BioSP, a service-oriented platform enables biometric system with advanced biometric data processing and management in a web services architecture; WebEnroll, a browser-based biometric enrollment and data management solution; and AwareID, an adaptive authentication platform provides biometric face and voice analysis, and document validation for cloud-based biometric application programming interfaces and turnkey services. In addition, the company offers biometrics applications, such as Nexa line, a biometric search and match SDKs including Nexa Fingerprint, Nexa Face, Nexa Iris, and Nexa Voice; and AwareXM, an interoperable fingerprint matching SDK that provides fingerprint minutiae extraction, template generation, and fingerprint authentication. Further, it sells imaging products used in medical and advanced imaging application; offers program management and software engineering services, and software maintenance services. The company sells its products, services, and solutions through systems integrators, direct, and original equipment manufacturers and value added resellers channel Aware, Inc. was incorporated in 1986 and is headquartered in Burlington, Massachusetts.

NASDAQ ended the session with Aware, Inc. sliding 4.41% to $1.63 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ rose 1.13% to $14,284.53, after four consecutive sessions in a row of gains, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Aware, Inc. has a trailing twelve months EPS of $-0.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12%.

Yearly Top and Bottom Value

Aware, Inc.’s stock is valued at $1.63 at 01:32 EST, way below its 52-week high of $2.01 and way above its 52-week low of $1.05.

Volume

Today’s last reported volume for Aware, Inc. is 2206 which is 97.4% below its average volume of 84971.

More news about Aware, Inc..

10. Lyft (LYFT) – -3.99%

Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. The company operates multimodal transportation networks that offer riders personalized and on-demand access to various mobility options. It provides Ridesharing Marketplace, which connects drivers with riders; Express Drive, a flexible car rentals program for drivers; Lyft Rentals that provides vehicles for long-distance trips; and a network of shared bikes and scooters in various cities to address the needs of riders for short trips. The company also integrates third-party public transit data into the Lyft app to offer riders various transportation options. In addition, it offers access to autonomous vehicles; centralized tools and enterprise transportation solutions, such as concierge transportation solutions for organizations; Lyft Pink subscription plans; Lyft Pass commuter programs; first-mile and last-mile services; and university safe rides programs. The company was formerly known as Zimride, Inc. and changed its name to Lyft, Inc. in April 2013. Lyft, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.

NASDAQ ended the session with Lyft dropping 3.99% to $10.16 on Tuesday while NASDAQ jumped 1.13% to $14,284.53.

Earnings Per Share

As for profitability, Lyft has a trailing twelve months EPS of $-2.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -193.79%.

More news about Lyft.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *